Associated Papers
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I et al.
Journal of Translational Medicine, 2024
38750555 (PubMed )
Supplement: 12967_2024_5227_MOESM14_ESM.xlsx › S14
Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation.
Sagan OA et al.
Frontiers in Oncology, 2023
Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y et al.
Nature, 2021
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma.
Bowman RL et al.
Life Science Alliance, 2021
34210801 (PubMed )
Supplement: LSA-2021-01135_TableS1.xlsx › Supp._Table_S1
Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y et al.
Jama Network Open, 2021
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
Hendifar A et al.
Jco Precision Oncology, 2021
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
33087175 (PubMed )
Supplement: 40478_2020_1040_MOESM1_ESM.xlsx › Sheet1
Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations.
Fischer CG et al.
Gastroenterology, 2019
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM et al.
Bmc Cancer, 2019
30665374 (PubMed )
Supplement: 12885_2019_5290_MOESM1_ESM.xlsx › CCNE1ms_forSupplData_FMOne_Pilo
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Ashktorab H et al.
Oncotarget, 2017
28002797 (PubMed )
Supplement: oncotarget-08-7852-s002.xlsx › BRAF.Illumina
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Shi E et al.
Journal of Translational Medicine, 2016
27974047 (PubMed )
Supplement: 12967_2016_1075_MOESM2_ESM.xlsx › Table_S6
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH et al.
Breast Cancer Research and Treatment, 2016
Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.
Metcalf AM et al.
Familial Cancer, 2014
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
Bodian DL et al.
Plos One, 2014
24728327 (PubMed )
Supplement: pone.0094554.s002.xlsx › Table_S1
Select a paper to view details